Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$38.62 USD

38.62
1,443,521

+0.26 (0.68%)

Updated Aug 7, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Parkinson's Space in Focus as Acorda Stops Tozadenant Trial

by Zacks Equity Research

Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.

    Zacks Equity Research

    Global In Vitro Diagnostic Market Booms: Stocks in Focus

    by Zacks Equity Research

    With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.

      Zacks Equity Research

      Company News For Nov 21, 2017

      by Zacks Equity Research

      Companies In The News are: DY,TWX,RHHBY,ITCI

        Zacks Equity Research

        Roche Reports Positive Data From Tecentriq Combination Study

        by Zacks Equity Research

        Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

          Swarup Gupta headshot

          Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss

          by Swarup Gupta

          Political uncertainty in the United Kingdom and commodity prices weighed on Europe's stocks over last week.

            Zacks Equity Research

            Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

            by Zacks Equity Research

            Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

              Zacks Equity Research

              Cancer Space Update: Label Expansion for Three Major Drugs

              by Zacks Equity Research

              This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

                Zacks Equity Research

                Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

                by Zacks Equity Research

                Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

                  Zacks Equity Research

                  Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?

                  by Zacks Equity Research

                  Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.

                    Zacks Equity Research

                    Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

                    by Zacks Equity Research

                    Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

                      Zacks Equity Research

                      Shire Gets Positive CHMP Opinion for Hemophilia A Drug

                      by Zacks Equity Research

                      Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                        Zacks Equity Research

                        Novartis (NVS) Arm's Biosimilars Study Results Encourage

                        by Zacks Equity Research

                        Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.

                          Zacks Equity Research

                          Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II

                          by Zacks Equity Research

                          Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.

                            Zacks Equity Research

                            Amgen Gets Positive CHMP Opinion to Expand Nplate's Label

                            by Zacks Equity Research

                            Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.

                              Zacks Equity Research

                              Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

                              by Zacks Equity Research

                              Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

                                Zacks Equity Research

                                Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

                                by Zacks Equity Research

                                Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

                                  by Arpita Dutt

                                  Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

                                    Zacks Equity Research

                                    Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

                                    by Zacks Equity Research

                                    Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.

                                      Zacks Equity Research

                                      Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

                                      by Zacks Equity Research

                                      Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.

                                        Zacks Equity Research

                                        Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up

                                        by Zacks Equity Research

                                        Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.

                                          Zacks Equity Research

                                          Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

                                          by Zacks Equity Research

                                          Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

                                            Zacks Equity Research

                                            Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View

                                            by Zacks Equity Research

                                            Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.

                                              Zacks Equity Research

                                              Mylan (MYL) Misses on Earnings and Sales Estimates in Q3

                                              by Zacks Equity Research

                                              Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.

                                                Zacks Equity Research

                                                ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up

                                                by Zacks Equity Research

                                                ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.

                                                  Zacks Equity Research

                                                  Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3

                                                  by Zacks Equity Research

                                                  Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.